http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008518882-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 2005-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-06-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2008518882-A |
| titleOfInvention | Anti-4-1BB antibody-containing drug composition for treating or preventing rheumatoid arthritis |
| abstract | The present invention relates to a pharmaceutical composition containing an anti-4-1BB antibody in an amount effective for prophylactic treatment of rheumatoid arthritis by proliferating CD11c + CD8 + T cells as an active ingredient and inducing CD4 + cell suppression together with a pharmaceutically acceptable carrier. The composition of the present invention is not toxic in a general immune reaction, and can remarkably alleviate the symptoms of progressive inflammatory or autoimmune joint inflammation induced by an antigen-specific immune response. Therefore, it is effective for prevention and treatment of joint diseases without rejection. [Selection] Figure 1 |
| priorityDate | 2004-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 350.